RxDoctor Payments Data

Michelle Johnson, NP

Family · Fort Worth, TXNPI 1801519087

Payments from drug & device makers

$1,396in general payments, 2019–2025

Across 14 payments — averaging $99.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$228
  • Boehringer Ingelheim$214
  • Dexcom, Inc.$126
  • Abbott$125
  • Novo Nordisk$119
  • AbbVie$112
  • plus $472 from 6 others

What the payments were for

  • Food & beverage$1,396100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,396 in reported general payments places this provider in the 75th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$27,994
Medicare patients
142
Services billed
429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide16$24,542
MounjaroTirzepatide11$15,488
EliquisApixaban11$12,439
Levothyroxine Sodium94$1,045
SynthroidLevothyroxine Sodium11$961
Albuterol Sulfate HfaAlbuterol Sulfate25$824
Estradiol29$806
Pantoprazole Sodium47$805
Atorvastatin Calcium78$749
Celecoxib26$746
Amitriptyline Hcl13$740
Baclofen14$729
Venlafaxine Hcl ErVenlafaxine Hcl22$724
Rosuvastatin Calcium73$692
Omeprazole33$666

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$119$24,54216 claims
Lilly USA, LLCMounjaro$107$15,48811 claims
AbbVieSynthroid$112$96111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 15,456 family providers in Texas.

Other family in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →